Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission inFIP1L1-PDGFRA-mutated hypereosinophilic syndrome

(2013) Grzegorz Helbig et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

(2013) Fanny Legrand et al.   MEDICINE

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

(2012) Peter Valent et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

(2011) Grzegorz Helbig et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

(2011) Grzegorz Helbig et al.   MEDICAL ONCOLOGY

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

(2010) P. Erben et al.   HAEMATOLOGICA

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Confidence intervals that match Fisher's exact or Blaker's exact tests

(2009) Michael P. Fay   BIOSTATISTICS

Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy

(2009) Princess U. Ogbogu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study

(2008) Georgia Metzgeroth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

(2008) J Gotlib et al.   LEUKEMIA

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

(2008) Nitin Jain et al.   LEUKEMIA RESEARCH